Decker H, Summers R G, Hutchinson C R
School of Pharmacy, University of Wisconsin, Madison 53706.
J Antibiot (Tokyo). 1994 Jan;47(1):54-63. doi: 10.7164/antibiotics.47.54.
The development of microorganisms with improved antibiotic production is an important goal in the commercialization of new pharmaceuticals or in lowering the cost of established drugs. We report a way to achieve this for biosynthetic intermediates of an antibiotic made by the polyketide pathway whose earliest steps involve a Type II multienzyme complex. Introduction of the tcmKLM beta-ketoacyl: ACP synthase and acyl carrier protein (ACP) genes or just the tcmM ACP gene into the tetracenomycin (Tcm) C-producing Streptomyces glaucescens wild-type strain, or its tcmN or tcmO blocked mutants, on high copy vectors under the control of strong promoters caused a 2 to 30-fold overproduction of Tcm D3 and some other biosynthetic intermediates (or shunt products) and a 25 to 30% increase in Tcm C production relative to the control strains carrying the plasmid vector only. However, Tcm C production was not greater than that obtained with the vector-free wild-type strain. The unexpected effect of increased ACP on Tcm D3 production suggests that the level of this protein can influence either the activity or level of the three other components of the Tcm polyketide synthase.
开发具有更高抗生素产量的微生物是新型药物商业化或降低现有药物成本的一个重要目标。我们报道了一种方法,可用于通过聚酮途径产生的抗生素的生物合成中间体来实现这一目标,该途径的最早步骤涉及II型多酶复合物。将tcmKLMβ-酮酰基:ACP合酶和酰基载体蛋白(ACP)基因,或仅tcmM ACP基因导入产四并苯霉素(Tcm)C的野生型天蓝色链霉菌菌株,或其tcmN或tcmO阻断突变体中,在强启动子控制下的高拷贝载体上,导致Tcm D3和其他一些生物合成中间体(或旁路产物)过量产生2至30倍,并且相对于仅携带质粒载体的对照菌株,Tcm C产量增加25%至30%。然而,Tcm C的产量并不高于无载体野生型菌株的产量。ACP增加对Tcm D3产量的意外影响表明,该蛋白的水平可能会影响Tcm聚酮合酶其他三个组分的活性或水平。